Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

43

Revenue 2017

Perjeta

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Perjeta was produced by Roche.

Roche in "unprecedented" launch period for new medicines

Roche in The star in Roche's show was once again its trio of HER2-positive breast cancer drugs - Herceptin (trastuzumab), Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine) - whose sales increased 9% to ... 12bn francs, driven mainly by a 31% growth for

Roche's melanoma combo "too expensive" for NHS use, says NICE

Roche's melanoma combo NICE arrived at a similar conclusion when it published a review of breast cancer drugs Perjeta (pertuzumab) in May and Kadcyla (trastuzumab-emtansine) at the end of last year.

Roche says Tecentriq "off to a good start"

Roche says Tecentriq Strong gains for Perjeta (pertuzumab) and Kadcyla (ado-trastuzumab emtansine) reinforced a 5% increase for HER2 stalwart Herceptin (trastuzumab) to 3.4bn francs.

NICE rejects Roche's breast cancer drug Perjeta

NICE rejects Roche's breast cancer drug Perjeta Perjeta is used alongside Herceptin or docetaxel to reduce the volume of breast tumours before surgery, making it easier to carry out the operation. ... The preliminary recommendations are open for comment until June 13, and any patient already on

Cancer drugs help Roche beat expectations in first quarter

Cancer drugs help Roche beat expectations in first quarter Co. Among Roche's newer products, breast cancer drug Perjeta (pertuzumab) grew 33% to CHF439m thanks to increased use in combination with Herceptin in HER2-positive breast cancer, while arthritis medication

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
11 London

11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...

Latest intelligence

brian smith science of the deal
The science of the deal
Business development is more like child-raising than you might think...
The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...

Infographics